Summit Therapeutics Inc. (SMMT) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $22.90M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $2.62M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $22.90M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $22.90M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | $2.62M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $2.62M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $2.62M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $20.38M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $22.90M | (m) | $2.62M | (m) | $122.20M | (m) | (m) | (m) | $1.80M | (m) |
| 2026-03-31 | (m) | $27.55M | (m) | $1.15M | (m) | $101.92M | (m) | (m) | (m) | $1.80M | (m) |
| 2025-12-31 | (m) | $20.29M | (m) | $2.28M | (m) | $92.32M | (m) | (m) | (m) | $1.83M | (m) |
| 2025-09-30 | (m) | $22.25M | (m) | $1.96M | (m) | $69.47M | (m) | (m) | (m) | $1.83M | (m) |
| 2025-06-30 | (m) | $22.98M | (m) | $1.49M | (m) | $64.60M | (m) | (m) | (m) | $1.84M | (m) |
| 2025-03-31 | (m) | $4.99M | (m) | $759.00K | (m) | $39.49M | (m) | (m) | (m) | $1.71M | (m) |
| 2024-12-31 | (m) | $4.64M | (m) | $1.80M | (m) | $46.81M | (m) | (m) | (m) | $1.63M | (m) |
| 2024-09-30 | (m) | $3.25M | (m) | $1.03M | (m) | $64.93M | (m) | (m) | (m) | $1.72M | (m) |
| 2024-06-30 | (m) | $3.34M | (m) | $806.00K | (m) | $146.78M | (m) | (m) | (m) | $1.60M | (m) |
| 2024-03-31 | (m) | $6.37M | (m) | $788.00K | (m) | $132.57M | (m) | (m) | (m) | $3.31M | (m) |
| 2023-12-31 | (m) | $2.67M | $0.00 | $717.00K | (m) | $125.26M | (m) | (m) | (m) | $1.56M | (m) |
| 2023-09-30 | (m) | $3.31M | $0.00 | $484.00K | $1.48M | $119.10M | (m) | $0.00 | $0.00 | $1.48M | $0.00 |
| 2023-06-30 | (m) | $987.00K | $0.00 | $619.00K | $1.51M | $117.77M | (m) | $0.00 | $0.00 | $1.51M | $0.00 |
| 2023-03-31 | (m) | $710.00K | $0.00 | $320.00K | $1.48M | $121.42M | (m) | $0.00 | $0.00 | $1.48M | $0.00 |
| 2022-12-31 | (m) | $355.00K | $0.00 | $662.00K | $1.43M | $537.51M | (m) | $0.00 | $0.00 | $1.43M | $0.00 |
| 2022-09-30 | (m) | $1.43M | $0.00 | $209.00K | $2.42M | $22.08M | (m) | $0.00 | $0.00 | $2.42M | $0.00 |
| 2022-06-30 | (m) | $3.57M | $3.23M | $265.00K | $2.59M | $44.40M | (m) | $3.23M | $0.00 | $2.59M | $0.00 |
| 2022-03-31 | (m) | $6.96M | $5.10M | $678.00K | $2.75M | $52.06M | (m) | $5.10M | $0.00 | $2.75M | $0.00 |
| 2021-12-31 | (m) | $4.37M | $7.94M | $897.00K | $2.78M | $30.09M | (m) | $7.94M | $0.00 | $2.78M | $0.00 |
| 2021-09-30 | (m) | $5.88M | $7.51M | $1.03M | $2.69M | $26.38M | (m) | $7.51M | $0.00 | $2.69M | $0.00 |
| 2021-06-30 | (m) | $6.95M | $7.50M | $661.00K | $2.69M | $26.09M | (m) | $7.14M | $365.00K | $2.69M | $0.00 |
| 2021-03-31 | (m) | $4.11M | $7.81M | $581.00K | $2.60M | $76.39M | (m) | $7.42M | $383.00K | $2.60M | $0.00 |
| 2020-12-31 | (m) | $6.14M | $8.94M | $729.00K | $2.51M | $23.05M | (m) | $8.37M | $569.00K | $2.51M | $0.00 |
| 2020-09-30 | (m) | $2.49M | $7.83M | $354.00K | $2.28M | $20.00M | (m) | $7.11M | $715.00K | $2.28M | $0.00 |
| 2020-06-30 | (m) | $3.09M | $5.37M | $672.00K | $2.66M | $19.00M | (m) | $4.52M | $856.00K | $2.66M | $0.00 |
| 2019-12-31 | (m) | $4.47M | $3.11M | $366.00K | $2.70M | $19.44M | (m) | $2.62M | $493.00K | $2.70M | $0.00 |
| 2019-01-31 | (m) | $5.80M | $5.52M | $458.00K | $2.43M | $23.75M | (m) | $4.43M | $1.09M | $2.43M | $0.00 |
| 2018-01-31 | (m) | $6.26M | $58.27M | $278.00K | $2.33M | $82.67M | (m) | $19.61M | $38.66M | $2.33M | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |